132 related articles for article (PubMed ID: 38146006)
1. BETA prime: a first-in-man phase 1 study of AdAPT-001, an armed oncolytic adenovirus for solid tumors.
Conley AP; Roland CL; Bessudo A; Gastman BR; Villaflor VM; Larson C; Reid TR; Caroen S; Oronsky B; Stirn M; Williams J; Burbano E; Coyle A; Barve MA; Wagle N; Abrouk N; Kesari S
Cancer Gene Ther; 2024 Apr; 31(4):517-526. PubMed ID: 38146006
[TBL] [Abstract][Full Text] [Related]
2. BETA PRIME: Phase I study of AdAPT-001 as monotherapy and combined with a checkpoint inhibitor in superficially accessible, treatment-refractory solid tumors.
Kesari S; Bessudo A; Gastman BR; Conley AP; Villaflor VM; Nabell LM; Madere D; Chacon E; Spencer C; Li L; Larson C; Reid T; Caroen S; Oronsky B; Stirn M; Williams J; Barve MA
Future Oncol; 2022 Sep; 18(29):3245-3254. PubMed ID: 35950603
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
[TBL] [Abstract][Full Text] [Related]
4. Preliminary efficacy and safety of YSCH-01 in patients with advanced solid tumors: an investigator-initiated trial.
He Y; Huang X; Li X; Liu H; Liu M; Tao J; Shan Y; Raza HK; Liu Y; Zhong W; Cao XP; Yang YY; Li R; Fang XL; Zhang KJ; Zhang R; Liu F
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38719544
[TBL] [Abstract][Full Text] [Related]
5. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial.
Zhang B; Huang J; Tang J; Hu S; Luo S; Luo Z; Zhou F; Tan S; Ying J; Chang Q; Zhang R; Geng C; Wu D; Gu X; Liu B
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837053
[TBL] [Abstract][Full Text] [Related]
7. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.
Chang J; Zhao X; Wu X; Guo Y; Guo H; Cao J; Guo Y; Lou D; Yu D; Li J
Cancer Biol Ther; 2009 Apr; 8(8):676-82. PubMed ID: 19242097
[TBL] [Abstract][Full Text] [Related]
8. First-in-human study of GFH018, a small molecule inhibitor of transforming growth factor-β receptor I inhibitor, in patients with advanced solid tumors.
Guo Y; Wang Z; Zhou H; Pan H; Han W; Deng Y; Li Q; Xue J; Ge X; Wang S; Wang J; Zhang Y; Zhao C; Zhu H; Wang Y; Shen H; Liu D; Li J
BMC Cancer; 2024 Apr; 24(1):444. PubMed ID: 38600507
[TBL] [Abstract][Full Text] [Related]
9. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
10. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors.
Garcia-Carbonero R; Bazan-Peregrino M; Gil-Martín M; Álvarez R; Macarulla T; Riesco-Martinez MC; Verdaguer H; Guillén-Ponce C; Farrera-Sal M; Moreno R; Mato-Berciano A; Maliandi MV; Torres-Manjon S; Costa M; Del Pozo N; Martínez de Villarreal J; Real FX; Vidal N; Capella G; Alemany R; Blasi E; Blasco C; Cascalló M; Salazar R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338084
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors.
Nemunaitis J; Tong AW; Nemunaitis M; Senzer N; Phadke AP; Bedell C; Adams N; Zhang YA; Maples PB; Chen S; Pappen B; Burke J; Ichimaru D; Urata Y; Fujiwara T
Mol Ther; 2010 Feb; 18(2):429-34. PubMed ID: 19935775
[TBL] [Abstract][Full Text] [Related]
12. A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE).
Machiels JP; Salazar R; Rottey S; Duran I; Dirix L; Geboes K; Wilkinson-Blanc C; Pover G; Alvis S; Champion B; Fisher K; McElwaine-Johnn H; Beadle J; Calvo E
J Immunother Cancer; 2019 Jan; 7(1):20. PubMed ID: 30691536
[TBL] [Abstract][Full Text] [Related]
13. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
[TBL] [Abstract][Full Text] [Related]
14. Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study.
Banerji U; van Herpen CML; Saura C; Thistlethwaite F; Lord S; Moreno V; Macpherson IR; Boni V; Rolfo C; de Vries EGE; Rottey S; Geenen J; Eskens F; Gil-Martin M; Mommers EC; Koper NP; Aftimos P
Lancet Oncol; 2019 Aug; 20(8):1124-1135. PubMed ID: 31257177
[TBL] [Abstract][Full Text] [Related]
15. Toxicology and biodistribution of AdAPT-001, a replication-competent type 5 adenovirus with a trap for the immunosuppressive cytokine, TGF-beta.
Larson C; Oronsky B; Abrouk NE; Oronsky A; Reid TR
Am J Cancer Res; 2021; 11(10):5184-5189. PubMed ID: 34765319
[TBL] [Abstract][Full Text] [Related]
16. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
[TBL] [Abstract][Full Text] [Related]
17. Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believing.
Conley A; Larson C; Oronsky B; Stirn M; Caroen S; Reid TR
J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38886116
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of the tumor-selective adenovirus enadenotucirev with or without paclitaxel in platinum-resistant ovarian cancer: a phase 1 clinical trial.
Moreno V; Barretina-Ginesta MP; García-Donas J; Jayson GC; Roxburgh P; Vázquez RM; Michael A; Antón-Torres A; Brown R; Krige D; Champion B; McNeish I
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34893524
[TBL] [Abstract][Full Text] [Related]
19. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
[TBL] [Abstract][Full Text] [Related]
20. The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study.
Yi L; Ning Z; Xu L; Shen Y; Zhu X; Yu W; Xie J; Meng Z
ESMO Open; 2024 Feb; 9(2):102239. PubMed ID: 38325225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
